Your healthy-aging goal

Can anything measurably slow biological aging in humans?

Epigenetic clocks, senescent-cell markers and other aging biomarkers. These are early research tools, not proof of a longer life.

Follow the signal, understand the certainty

Some ideas are promising, some are early, and some have disappointed. We show Evidence, Results and Safety separately so you can see both the possibility and the uncertainty — see how we weigh evidence.

Evidence is emerging

Human findings point in more than one direction. This is an active question rather than a settled answer.

Listed alphabetically — not ranked

Biomarker — does not establish a health benefit

Blood & plasma

Therapeutic plasma exchange / plasma dilution

Blood- and plasma-based procedures that remove, replace or dilute circulating plasma components. AgeBeacon tracks human evidence relevant to aging separately from established disease-specific uses of therapeutic plasma exchange.

1 healthy-aging outcome area tracked

Human research
Signal · Biological aging
Safety

1 beneficial, 0 neutral, 1 harmful and 0 mixed interpreted result(s); 0 remain unknown. Counts describe linked results, not effect size or certainty.

Studied without a demonstrated benefit

Human studies have looked at this outcome but the interpreted results shown here have not demonstrated a benefit.

Listed alphabetically — not ranked

Biomarker — does not establish a health benefit

Senolytic candidate

Dasatinib + Quercetin

An experimental senolytic combination being studied for whether clearing some senescent cells can improve age-related function.

4 healthy-aging outcome areas tracked

Human research: 3 outcome assessment(s) still require classification.
Signal · Biological aging
Safety

3 outcome assessment(s) still require classification.

0 beneficial, 1 neutral, 0 harmful and 0 mixed interpreted result(s); 5 remain unknown. Counts describe linked results, not effect size or certainty.

Biomarker — does not establish a health benefit

Senolytic candidate

Fisetin

A plant flavonoid being investigated for senolytic activity and its potential effects on age-related cellular dysfunction.

1 healthy-aging outcome area tracked

Human research: 3 outcome assessment(s) still require classification.
Signal · Biological aging
Safety

3 outcome assessment(s) still require classification.

0 beneficial, 1 neutral, 0 harmful and 0 mixed interpreted result(s); 0 remain unknown. Counts describe linked results, not effect size or certainty.

Biomarker — does not establish a health benefit

Drug / geroscience

Metformin

A widely used diabetes medicine being studied for whether its metabolic effects may influence aging-related health beyond glucose control.

7 healthy-aging outcome areas tracked

Human research: 11 outcome assessment(s) still require classification.
Signal · Biological aging
Safety

11 outcome assessment(s) still require classification.

0 beneficial, 1 neutral, 0 harmful and 0 mixed interpreted result(s); 1 remain unknown. Counts describe linked results, not effect size or certainty.

Biomarker — does not establish a health benefit

Senolytic candidate

Quercetin

A common plant flavonoid studied in longevity research, including as part of experimental senolytic combinations.

4 healthy-aging outcome areas tracked

Human research: 3 outcome assessment(s) still require classification.
Signal · Biological aging
Safety

3 outcome assessment(s) still require classification.

0 beneficial, 1 neutral, 0 harmful and 0 mixed interpreted result(s); 5 remain unknown. Counts describe linked results, not effect size or certainty.

Other goals

Longevity Muscle Brain Energy Metabolism Cardiovascular Inflammation

Ask a question